Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Tarceva Approved In The EU for Maintenance Use in Advanced Lung Cancer

By Pharmaceutical Processing | April 29, 2010

Roche announced today that the European Commission has approved Tarceva® (erlotinib) as monotherapy for maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (known as ‘stable disease’) after platinum-based initial chemotherapy. The approval is based on data from the pivotal SATURN study which showed that compared to placebo Tarceva gave patients with stable disease a 39% improvement in overall survival (OS) and a 2.3 month improvement in median survival (11.9 months vs. 9.6 months.) 

Patients with advanced NSCLC whose tumours remain largely unchanged after initial chemotherapy (‘stable disease’) have tumours that progress faster, are more resistant to further lines of chemotherapy and have a poorer prognosis compared to patients with a complete or partial response to initial chemotherapy. When entering the pivotal SATURN study approximately half of patients randomised after initial chemotherapy had stable disease.

“The approval of Tarceva for maintenance use in stable, advanced non-small cell lung cancer offers patients a much needed additional treatment option and reinforces the role that this medicine has to play in treating this devastating disease,” said Hal Barron, M.D., executive vice president, Global Development and chief medical officer. “Instead of waiting for their disease to progress, patients can now opt to continue to keep it under control, which may help them live longer.”

Tarceva has been approved in the EU since September 2005 and in the US since November 2004 for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. Tarceva also recently gained approval from the U.S. Food and Drug Administration (FDA) for maintenance treatment of NSCLC

 

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE